DNASE1 and COVID-19: Pulmozyme®, also known as dornase alfa, is a commercially available recombinant human DNase-I that is approved for the treatment of cystic fibrosis16 and currently used in a prospective, randomized, multicenter, double-blinded, placebo-controlled clinical trial to reduce the incidence of moderate-to-severe hypoxemia in ventilated trauma patients17 and also diminished NETs formation in COVID-19 patients18.